Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxim Norkin

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Blood Advances|February 15, 2018
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamideShannon R McCurdy, Mei-Jie Zhang, Andrew St Martin, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2019
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide ConditioningJeannine S McCune, Tao Wang, Khalid Bo-Subait, et al.
Blood|February 18, 2016
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysisPierre Teira, Minoo Battiwalla, Muthalagu Ramanathan, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation CentersChloe Anthias, Bronwen E Shaw, Deidre M Kiefer, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
The Lancet. Haematology|December 28, 2019
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort studyKasiani C Myers, Elissa Furutani, Edie Weller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromesChristine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Blood Advances|February 15, 2018
Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamideShannon R McCurdy, Mei-Jie Zhang, Andrew St Martin, et al.
Journal for Immunotherapy of Cancer|October 25, 2023
PD-1-expressing macrophages and CD8 T cells are independent predictors of clinical benefit from PD-1 inhibition in advanced mesotheliomaKrisztian Homicsko, Panagiota Zygoura, Maxim Norkin, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 16, 2019
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide ConditioningJeannine S McCune, Tao Wang, Khalid Bo-Subait, et al.
Blood|February 18, 2016
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysisPierre Teira, Minoo Battiwalla, Muthalagu Ramanathan, et al.
Blood Advances|November 9, 2021
Abatacept for GVHD prophylaxis can reduce racial disparities by abrogating the impact of mismatching in unrelated donor stem cell transplantationMuna Qayed, Benjamin Watkins, Scott Gillespie, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 25, 2015
Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation CentersChloe Anthias, Bronwen E Shaw, Deidre M Kiefer, et al.
Transplantation and Cellular Therapy|December 30, 2022
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical TrialBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
The Lancet. Haematology|December 28, 2019
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort studyKasiani C Myers, Elissa Furutani, Edie Weller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 27, 2021
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant CyclophosphamideBronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 16, 2014
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromesChristine N Duncan, Navneet S Majhail, Ruta Brazauskas, et al.
Pageof 6